[1]
I. P. Hall and M. Pirmohamed, Pharmacogenetics. New York: Taylor & Francis, 2006 [Online]. Available: https://doi.org/10.3109/9781420016697
[2]
Gibb, Alasdair J., Foreman, John C., and Johansen, Torben, Textbook of receptor pharmacology, 3rd ed. Boca Raton, FL: CRC Press, 2011.
[3]
Kenakin, Terrence P., A pharmacology primer: theory, applications, and methods, 3rd ed. Burlington, MA: Elsevier Academic Press, 2009 [Online]. Available: https://www-sciencedirect-com.libproxy.ucl.ac.uk/book/9780123745859/a-pharmacology-primer
[4]
Burton, Paul, Palmer, Lyle, and Smith, George Davey, An introduction to genetic epidemiology, vol. Health&society series. Bristol: Policy Press, 2011.
[5]
M. V. Holmes, T. Shah, C. Vickery, L. Smeeth, A. D. Hingorani, and J. P. Casas, ‘Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies’, PLoS ONE, vol. 4, no. 12, Dec. 2009, doi: 10.1371/journal.pone.0007960.
[6]
S. E. Humphries and A. Hingorani, ‘Pharmacogenetics: Progress, pitfalls and clinical potential for coronary heart disease’, Vascular Pharmacology, vol. 44, no. 2, pp. 119–125, Feb. 2006, doi: 10.1016/j.vph.2005.10.003.
[7]
R. R. Neubig, ‘International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology’, Pharmacological Reviews, vol. 55, no. 4, pp. 597–606, Dec. 2003, doi: 10.1124/pr.55.4.4.
[8]
R. J. Lefkowitz, ‘Historical review: A brief history and personal retrospective of seven-transmembrane receptors’, Trends in Pharmacological Sciences, vol. 25, no. 8, pp. 413–422, Aug. 2004, doi: 10.1016/j.tips.2004.06.006.
[9]
R. Seifert and K. Wenzel-Seifert, ‘Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors’, Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 366, no. 5, pp. 381–416, Nov. 2002, doi: 10.1007/s00210-002-0588-0.
[10]
A. J. Thompson, H. A. Lester, and S. C. R. Lummis, ‘The structural basis of function in Cys-loop receptors’, Quarterly Reviews of Biophysics, vol. 43, no. 04, pp. 449–499, Nov. 2010, doi: 10.1017/S0033583510000168.
[11]
Kirkwood, Betty R., Kirkwood, Betty R., and Sterne, Jonathan A. C., Essential medical statistics, 2nd ed. Malden, Mass: Blackwell Science, 2003.
[12]
‘New Perspectives for the Elucidation of Genetic Disorders’, doi: 520679. [Online]. Available: http://www.sciencedirect.com/science/article/pii/S0002929707611872
[13]
H.-H. Ropers, ‘New Perspectives for the Elucidation of Genetic Disorders’, The American Journal of Human Genetics, vol. 81, no. 2, pp. 199–207, Aug. 2007, doi: 10.1086/520679.
[14]
J. N. Hirschhorn and M. J. Daly, ‘Genome-wide association studies for common diseases and complex traits’, Nature Reviews Genetics, vol. 6, no. 2, pp. 95–108, Feb. 2005, doi: 10.1038/nrg1521.
[15]
D. Botstein and N. Risch, ‘Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease’, Nature Genetics, vol. 33, no. 3s, pp. 228–237, Mar. 2003, doi: 10.1038/ng1090.
[16]
M. R. Capecchi, ‘Essay: Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century’, Nature Reviews Genetics, vol. 6, no. 6, pp. 507–512, Jun. 2005, doi: 10.1038/nrg1619.
[17]
R. R. Brinkman, M.-P. Dubé, G. A. Rouleau, A. C. Orr, and M. E. Samuels, ‘Human monogenic disorders — a source of novel drug targets’, Nature Reviews Genetics, vol. 7, no. 4, pp. 249–260, Mar. 2006, doi: 10.1038/nrg1828.
[18]
T. P. O’Connor and R. G. Crystal, ‘Genetic medicines: treatment strategies for hereditary disorders’, Nature Reviews Genetics, vol. 7, no. 4, pp. 261–276, Apr. 2006, doi: 10.1038/nrg1829.
[19]
S. E. Antonarakis and J. S. Beckmann, ‘Mendelian disorders deserve more attention’, Nature Reviews Genetics, vol. 7, no. 4, pp. 277–282, Mar. 2006, doi: 10.1038/nrg1826.
[20]
‘Table of contents : Nature Reviews Genetics Focus on Monogenic disorders’. .
[21]
G. K. Hansson and P. Libby, ‘The immune response in atherosclerosis: a double-edged sword’, Nature Reviews Immunology, vol. 6, no. 7, pp. 508–519, Jun. 2006, doi: 10.1038/nri1882.
[22]
‘Atherosclerosis — An Inflammatory Disease — NEJM’. .
[23]
S. Yusuf et al., ‘Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study’, The Lancet, vol. 364, no. 9438, pp. 937–952, Sep. 2004, doi: 10.1016/S0140-6736(04)17018-9.
[24]
S. Kathiresan et al., ‘Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants’, Nature Genetics, vol. 41, no. 3, pp. 334–341, Feb. 2009, doi: 10.1038/ng.327.
[25]
J. M. Bras and A. Singleton, ‘Genetic susceptibility in Parkinson’s disease’, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1792, no. 7, pp. 597–603, Jul. 2009, doi: 10.1016/j.bbadis.2008.11.008.
[26]
D. Altshuler, M. J. Daly, and E. S. Lander, ‘Genetic Mapping in Human Disease’, Science, vol. 322, no. 5903, pp. 881–888, Nov. 2008, doi: 10.1126/science.1156409.
[27]
M. I. McCarthy et al., ‘Genome-wide association studies for complex traits: consensus, uncertainty and challenges’, Nature Reviews Genetics, vol. 9, no. 5, pp. 356–369, May 2008, doi: 10.1038/nrg2344.
[28]
P. M. Abou-Sleiman, M. M. K. Muqit, and N. W. Wood, ‘Expanding insights of mitochondrial dysfunction in Parkinson’s disease’, Nature Reviews Neuroscience, vol. 7, no. 3, pp. 207–219, Mar. 2006, doi: 10.1038/nrn1868.
[29]
Sham, P., Statistics in human genetics. Chichester: Wiley, 2007.
[30]
Thomas, Duncan C., Statistical methods in genetic epidemiology. New York: Oxford University Press, 2004.
[31]
D. J. Balding, ‘A tutorial on statistical methods for population association studies’, Nature Reviews Genetics, vol. 7, no. 10, pp. 781–791, Oct. 2006, doi: 10.1038/nrg1916.
[32]
Neale, Benjamin M. and International Workshop of Twin and Family Studies, Statistical genetics: gene mapping through linkage and association. Abingdon: Taylor & Francis, 2008.
[33]
Bishop, M., Cannings, C., and Balding, D. J., Handbook of statistical genetics, 3rd ed. Chichester: John Wiley, 2007 [Online]. Available: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119487845
[34]
Foulkes, Andrea S., Applied statistical genetics with R: for population-based association studies, vol. Use R! Dordrecht: Springer, 2009.
[35]
A. K. Daly, ‘Genome-wide association studies in pharmacogenomics’, Nature Reviews Genetics, vol. 11, no. 4, pp. 241–246, Apr. 2010, doi: 10.1038/nrg2751.
[36]
M. V. Holmes, T. Shah, C. Vickery, L. Smeeth, A. D. Hingorani, and J. P. Casas, ‘Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies’, PLoS ONE, vol. 4, no. 12, Dec. 2009, doi: 10.1371/journal.pone.0007960.
[37]
A. J. X. Lee and C. Swanton, ‘Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics’, Biochemical Pharmacology, vol. 83, no. 8, pp. 1013–1020, Apr. 2012, doi: 10.1016/j.bcp.2011.12.008.
[38]
M. V. Holmes, ‘CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular EventsA Systematic Review and Meta-analysis’, JAMA: The Journal of the American Medical Association, vol. 306, no. 24, Dec. 2011, doi: 10.1001/jama.2011.1880.
[39]
Orengo, Christine Ann, Jones, David Tudor, and Thornton, Janet M., Bioinformatics: genes, proteins and computers. Oxford: BIOS, 2003 [Online]. Available: https://www.vlebooks.com/Product/Index/2052147?page=0&startBookmarkId=-1
[40]
Zvelebil, Marketa J. and Baum, Jeremy O., Understanding bioinformatics. New York: Garland Science, 2008 [Online]. Available: https://bibliu.com/app/#/view/books/9781136976964/pdf2htmlex/index.html#page_Cover
[41]
Lesk, Arthur M., Introduction to bioinformatics, 3rd ed. Oxford: Oxford University Press, 2008.